The Latest Breaking News from Centene

Upgrades

Centene Corporation (NYSE:CNC) has agreed to sell Magellan Rx to Prime Therapeutics LLC and PANTHERx Rare to a consortium of The Vistria Group, General Atlantic, and Nautic Partners.  Centene expects to receive approximately $2.8 billion in aggregate proceeds from the transactions. Magellan Rx is a comprehensive pharmacy solutions organization with specialty drug management, Medicaid administration, and comprehensive pharmacy…

The COVID-19 pandemic has been a blessing for the healthcare plan industry due to increased healthcare spending. In addition, with the rising healthcare needs of an aging population, the industry’s prospects look bright. Clover Health Investments, Corp. (CLOV) and Centene (CNC) should benefit from this trend. But which of these…

Over the past 3 months, 9 analysts have published their opinion on Centene (NYSE:CNC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Centene Corporation (NYSE: CNC) has reported Q4 adjusted EPS of $1.01,

  Centene (NYSE:CNC) reported its Q4 earnings results on Tuesday, February 8, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

NHS England faces a legal challenge against a decision to approve a 'change in control' of primary care provider AT Medics

Judicial review hearing could overturn Centene takeover branded by opponents as ‘NHS privatisation by stealth’

French CAC 40 Index gained around 1% this morning, partially recovering from previous session’s 4% plunge, as investors await the policy decision from the Federal Reserve tomorrow. Investors, meanwhile, focused on some notable insider trades.